|Articles|August 10, 2022
Validation of ICON™ Automated Cell Counting and Viability Assay (August 2022)
Author(s)Advanced Instruments
This benchmarking study compares the Advanced Instruments Solentim ICON™ viability assay to the performance of a commercially available cell counter. The results demonstrate lower variation, increased precision, and time savings.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Trending on BioPharm International
1
Charles River Incubator Cohort to Accelerate CGT Development
2
BioPharma By The Numbers: Batch Failures in Biopharma Manufacturing
3
FDA Decision Accelerates Rare Disease Gene Therapy Regulatory Pathways
4
GSK and Oxford BioTherapeutics Drive Antibody-Based Cancer Drug Discovery at Industry Scale
5
